Featured releases

Consumer Wearable Introduces Continuous Blood-Oxygen and Sleep Memory Tracking

First Consumer Wearable Delivers Continuous Blood-Oxygen & Sleep-Memory Insights, Validated Against Hospital-Grade Standards

San Francisco, Calif. – November 25, 2025 NeuroRing Inc. today announced U.S. retail availability of the NeuroRing Gen-3, the first consumer wearable that simultaneously records continuous blood-oxygen saturation (SpO₂) and sleep-memory consolidation cycles without a finger probe or overnight lab visit. The titanium ring samples SpO₂ at 1 Hz through the night and applies an on-device neural net—trained on 1.8 million labeled polysomnography epochs—to identify periods when the brain converts short-term memories to long-term storage, a process known as sleep-dependent memory consolidation.

Third-party validation run at the Stanford Sleep Medicine Center found the device’s SpO₂ mean absolute error 2.1 % versus FDA-cleared Masimo MightySat Rx, matching the accuracy of the Apple Watch Series 7 (2.2 %) while delivering 6× more nightly data points thanks to the ring’s optical wrap-around sensor.

For sleep staging, epoch-by-epoch agreement with polysomnography reached κ = 0.66, outperforming wrist-worn competitors and meeting the clinical “acceptable” threshold set by the American Academy of Sleep Medicine for unattended sleep tracking.

Market demand is rising fast: the global pulse-oximeter segment is projected to grow 7 % annually through 2030, fueled by 74 % of U.S. adults who now say they want “hospital-grade” metrics at home, according to a 2025 Medi-Tech Insights survey.

Meanwhile, peer-reviewed studies link untreated nocturnal oxygen desaturation to a 28 % increase in cardiovascular events within five years, driving insurers to expand reimbursement for remote monitoring.

“Consumers no longer want snapshots—they want a movie of their night,” said Dr. Lena Cho, co-founder & CEO of NeuroRing. “By coupling second-by-second SpO₂ with memory-tracking algorithms, we give users a single score that answers two questions: Did I breathe well, and did my brain actually store what I learned today? Early beta testers improved overnight memory-retention scores 18 % after two weeks of guided breathing prompts triggered by the ring.”

The device launches with a ResearchKit-ready API, allowing physicians to download de-identified raw data for chronic obstructive pulmonary disease (COPD) or sleep-apnea review. Battery life reaches five nights on a 30-min charge, and all processing is done on-device to comply with HIPAA and GDPR.

NeuroRing Gen-3 is priced at $349 and ships starting December 2 from NeuroRing.com, Amazon, and 240 Best Buy Health hubs. A prescription-only “Pro” dashboard that exports CPT-coded reports for telehealth visits will be available in Q1 2026.

About NeuroRing Inc.

Founded in 2021 by neuroscientists from Stanford and UCSF, NeuroRing is a digital-health company focused on invisible, clinical-grade sensing. The company has raised $42 million in Series A funding led by Andreessen Horowitz and holds 12 issued patents on opto-neural signal processing.